Healthcare
U.S. Stem Cell, Inc.(USRM)
Live Price
Offline$0.0001
+0.00% today
1Y Change
-50.00%
Window
Jun 20, 2025 โ Jun 18, 2026
- Market Cap
- โ
- Revenue Growth
- -59.1%
- EPS Growth
- +32.4%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 20, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
U.S. Stem Cell, Inc. (USRM) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 50.0% across the available one-year price window (Jun 20, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -59.1%, EPS growth of +32.4%, a dividend yield of 0.0%. What stands out right now is revenue -59.1%, EPS +32.4%, free cash flow +71.2% with operating margin -2096.9% and ROIC 29.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines USRM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-59.1% vs +7.6% peer median
Operating Margin
Below sector median
-2096.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2022 was reported on Dec 31, 2022, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -59.1% and EPS is at +32.4%, with operating margin around -2096.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -50.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2022 Dec 31, 2022 | โ | -50.0% | -50.0% | -50.0% |
2022 Nov 9, 2022 | โ | -50.0% | -50.0% | -50.0% |
2022 May 23, 2022 | โ | -50.0% | -50.0% | -50.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
USRM
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
USRM Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for USRM and SPY.
Company Overview
U.S. Stem Cell, Inc.
Other OTC
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.
- Leadership
- Michael Tomas
- IPO Date
- Feb 19, 2008
- Employees
- 11
- Street Address
- 1560 Sawgrass Corporate Parkway
- Mailing
- Sunrise, FL, 33323
- Region
- Sunrise, FL, US
- Reporting Currency
- USD
- Investor Line
- 954 835 1500
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.8
- Price/Book
- โ
Growth
- Revenue
- -59.1%
- EPS
- +32.4%
- Free Cash Flow
- +71.2%
Profitability
- Gross Margin
- 71.0%
- Operating Margin
- -2096.9%
- Net Margin
- -3483.2%
- ROE
- 20.8%
- ROIC
- 29.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.